Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

Investing.com -- Shares of Allurion Technologies (NYSE: ALUR) skyrocketed by 350% following the company's announcement of its plans to initiate a clinical study aimed at optimizing muscle mass during ...

29,885 people played the daily Crossword recently. Can you solve it faster than others?29,885 people played the daily Crossword recently. Can you solve it faster than others? A woman regained ...

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an obesity drug.

智通财经获悉，周四，Allurion(ALUR.US)股价收涨超21%；截至发稿，股价在盘后交易中进一步飙升80%，此前有消息称该公司计划将 ...

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a ...

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive securities purchase ...